FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093179967> ?p ?o ?g. }

• W3093179967 abstract "High-risk rhabdomyosarcoma (RMS) occurring in childhood to young adulthood is associated with a poor prognosis; especially children above the age of ten with advanced stage alveolar RMS still succumb to the disease within a median of two years. The advent of chimeric antigen receptor (CAR)-engineered T cells marked significant progress in the treatment of refractory B cell malignancies, but experience for solid tumors has proven challenging. We speculate that this is at least in part due to the poor quality of the patient’s own T cells and therefore propose using CAR-modified cytokine-induced killer (CIK) cells as effector cells. CIK cells are a heterogeneous population of polyclonal T cells that acquire phenotypic and cytotoxic properties of natural killer (NK) cells through the cultivation process, becoming so-called T-NK cells. CIK cells can be genetically modified to express CARs. They are minimally alloreactive and can therefore be acquired from haploidentical first-degree relatives. Here, we explored the potential of ERBB2-CAR-modified random-donor CIK cells as a treatment for RMS in xenotolerant mice bearing disseminated high-risk RMS tumors. In otherwise untreated mice, RMS tumors engrafted 13 to 35 days after intravenous tumor cell injection, as shown by in vivo bioluminescence imaging, immunohistochemistry, and polymerase chain reaction for human gDNA, and mice died shortly thereafter (median/range: 62/56-66 days, n=5). Wild-type (WT) CIK cells given at an early stage delayed and eliminated RMS engraftment in 4 of 6 (67%) mice, while ERBB2-CAR CIK cells inhibited initial tumor load in 8 of 8 (100%) mice. WT CIK cells were detectable but not as active as CAR CIK cells at distant tumor sites. CIK cell therapies during advanced RMS delayed but did not inhibit tumor progression compared to untreated controls. ERBB2-CAR CIK cell therapy also supported innate immunity as evidenced by selective accumulation of NK and T-NK cell subpopulations in disseminated RMS tumors, which was not observed for WT CIK cells. Our data underscore the power of heterogenous immune cell populations (T, NK, and T-NK cells) to control solid tumors, which can be further enhanced with CARs, suggesting ERBB2-CAR CIK cells as a potential treatment for high-risk RMS." @default.
• W3093179967 created "2020-10-22" @default.
• W3093179967 creator A5002564888 @default.
• W3093179967 creator A5014817551 @default.
• W3093179967 creator A5026973115 @default.
• W3093179967 creator A5056700746 @default.
• W3093179967 creator A5056771055 @default.
• W3093179967 creator A5059562009 @default.
• W3093179967 creator A5060684796 @default.
• W3093179967 creator A5063179666 @default.
• W3093179967 creator A5066552100 @default.
• W3093179967 creator A5081650438 @default.
• W3093179967 creator A5082749079 @default.
• W3093179967 creator A5083142416 @default.
• W3093179967 date "2020-10-19" @default.
• W3093179967 modified "2023-10-16" @default.
• W3093179967 title "ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma" @default.
• W3093179967 cites W1564959198 @default.
• W3093179967 cites W1824189202 @default.
• W3093179967 cites W1964438000 @default.
• W3093179967 cites W1966155043 @default.
• W3093179967 cites W1994993231 @default.
• W3093179967 cites W1997445678 @default.
• W3093179967 cites W2016523043 @default.
• W3093179967 cites W2027863358 @default.
• W3093179967 cites W2032174355 @default.
• W3093179967 cites W2033439695 @default.
• W3093179967 cites W2055606489 @default.
• W3093179967 cites W2087654677 @default.
• W3093179967 cites W2090823859 @default.
• W3093179967 cites W2101189819 @default.
• W3093179967 cites W2120045046 @default.
• W3093179967 cites W2126189632 @default.
• W3093179967 cites W2127736279 @default.
• W3093179967 cites W2133114658 @default.
• W3093179967 cites W2143709274 @default.
• W3093179967 cites W2144751606 @default.
• W3093179967 cites W2162948791 @default.
• W3093179967 cites W2163544987 @default.
• W3093179967 cites W2164524832 @default.
• W3093179967 cites W2241784197 @default.
• W3093179967 cites W2352290668 @default.
• W3093179967 cites W2409807463 @default.
• W3093179967 cites W2462177828 @default.
• W3093179967 cites W2561849178 @default.
• W3093179967 cites W2741687714 @default.
• W3093179967 cites W2787301955 @default.
• W3093179967 cites W2787621143 @default.
• W3093179967 cites W2789932534 @default.
• W3093179967 cites W2790362775 @default.
• W3093179967 cites W2790715303 @default.
• W3093179967 cites W2791064759 @default.
• W3093179967 cites W2864786814 @default.
• W3093179967 cites W2884835745 @default.
• W3093179967 cites W2896974909 @default.
• W3093179967 cites W2911543360 @default.
• W3093179967 cites W2911909558 @default.
• W3093179967 cites W2947556677 @default.
• W3093179967 cites W2948485623 @default.
• W3093179967 cites W2955560354 @default.
• W3093179967 cites W2961879220 @default.
• W3093179967 cites W2969529752 @default.
• W3093179967 cites W2980245695 @default.
• W3093179967 cites W2984205493 @default.
• W3093179967 cites W2985716879 @default.
• W3093179967 cites W3015997773 @default.
• W3093179967 cites W3016877653 @default.
• W3093179967 cites W3020695918 @default.
• W3093179967 cites W3043123256 @default.
• W3093179967 doi "https://doi.org/10.3389/fimmu.2020.581468" @default.
• W3093179967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7641627" @default.
• W3093179967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33193388" @default.
• W3093179967 hasPublicationYear "2020" @default.
• W3093179967 type Work @default.
• W3093179967 sameAs 3093179967 @default.
• W3093179967 citedByCount "19" @default.
• W3093179967 countsByYear W30931799672021 @default.
• W3093179967 countsByYear W30931799672022 @default.
• W3093179967 countsByYear W30931799672023 @default.
• W3093179967 crossrefType "journal-article" @default.
• W3093179967 hasAuthorship W3093179967A5002564888 @default.
• W3093179967 hasAuthorship W3093179967A5014817551 @default.
• W3093179967 hasAuthorship W3093179967A5026973115 @default.
• W3093179967 hasAuthorship W3093179967A5056700746 @default.
• W3093179967 hasAuthorship W3093179967A5056771055 @default.
• W3093179967 hasAuthorship W3093179967A5059562009 @default.
• W3093179967 hasAuthorship W3093179967A5060684796 @default.
• W3093179967 hasAuthorship W3093179967A5063179666 @default.
• W3093179967 hasAuthorship W3093179967A5066552100 @default.
• W3093179967 hasAuthorship W3093179967A5081650438 @default.
• W3093179967 hasAuthorship W3093179967A5082749079 @default.
• W3093179967 hasAuthorship W3093179967A5083142416 @default.
• W3093179967 hasBestOaLocation W30931799671 @default.
• W3093179967 hasConcept C111335760 @default.
• W3093179967 hasConcept C114684123 @default.
• W3093179967 hasConcept C142724271 @default.
• W3093179967 hasConcept C154317977 @default.
• W3093179967 hasConcept C161997846 @default.
• W3093179967 hasConcept C167672396 @default.
• W3093179967 hasConcept C202751555 @default.

• next